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Most tumour cells are sensitive to TRAIL-induced apoptosis, but not normal cells; thus, cancer therapy using TRAIL is expected
clinically. Several tumour cells are resistant to TRAIL-induced apoptosis, and various mechanisms of such resistance were reported in
individual cases. In this study, we established a TRAIL-resistant glioma cell line, which completely lacked TRAIL receptors. In addition,
this tumour cell line had wild-type p53 tumour-suppressive gene, suggesting new mechanisms for tumour cells to expand and escape
from immune surveillance. The present study further explored the mechanisms that determine the sensitivity to TRAIL. We show
that genotoxic agents such as cisplatin, doxorubicin and camptothecin, in addition to UV radiation, can induce TRAIL-R2 on the cell
surface of TRAIL receptor-negative tumour cells. Newly synthesised TRAIL-R2 is functional, so apoptosis is effectively induced by
TRAIL, but it is significantly inhibited by constitutive expression of dominant-negative p53. In addition, apoptosis induced by
pretreatment of genotoxic agents and additional stimulation of TRAIL is efficiently inhibited by either antagonistic anti-TRAIL-R2
antibody or pan-caspase inhibitor z-VAD-FMK. Taken together, these findings suggest that resistance to TRAIL by lack of TRAIL
receptors on glioma is restored by genotoxic agents, which support the new strategies for tumour killing by TRAIL-bearing cytotoxic
cells in combination with genotoxic treatment.
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TRAIL/Apo2L, a cytotoxic ligand that is a member of the TNF
family (Wiley et al, 1995; Pitti et al, 1996), and its specific receptors
(Degli-Esposti et al, 1997a; MacFarlane et al, 1997; Marsters et al,
1997; Pan et al, 1997a,b; Screaton et al, 1997; Sheridan et al, 1997;
Schneider et al, 1997; Ashkenazi and Dixit, 1999a) have been
identified. Similar to other TNF family molecules such as TNF-a,
FasL or TWEAK, TRAIL can induce apoptosis by ligation to its
specific cell surface receptors (TRAIL-Rs). Although TRAIL can
induce apoptosis in transformed cells of diverse origin, little or no
effect on normal cells has been reported (Zhang et al, 2000). In
contrast to FasL, the administration of which causes lethal liver
failure in mice (Tanaka et al, 1997), injection of TRAIL was
suggested not to reveal general toxicity (Ashkenazi et al, 1999b;
Walczak et al, 1999), although it was recently shown to induce
damage in human hepatocytes and normal brain tissues (Jo et al,
2000; Nitsch et al, 2000).
The regulation of TRAIL-induced apoptosis was suggested to be
mostly controlled by the expression of TRAIL receptors. Among
TRAIL receptors, two distinct receptors for TRAIL, TRAIL-R1
(DR4) and TRAIL-R2 (DR5), which have intracellular death
domains, have been identified. Two other receptors for TRAIL,
TRAIL-R3 (DcR1), which has no cytoplasmic death domain, and
TRAIL-R4 (DcR2), which has an incomplete death domain, have
also been identified. TRAIL-R3 and -R4 were suggested to act as
decoy receptors and to inhibit TRAIL-induced apoptosis by
competition with TRAIL-R1 and -R2. Although the expression of
TRAIL-R1 or -R2 is necessary to induce the death signal of TRAIL,
the expression of TRAIL-R3 and -R4 does not necessarily correlate
with cell sensitivity to TRAIL (Griffith et al, 1998; Hao et al, 2001).
Recently, mutations of TRAIL-R1 and -R2 have been reported as
the mechanism for tumour cells to be resistant to TRAIL in breast
cancers (Shin et al, 2001). On the contrary, the expression of
intracellular inhibitors of apoptosis has been proposed to be an
essential determinant of cell sensitivity to TRAIL. The expression
level of FLICE-inhibitory protein (FLIP) was higher in the TRAIL-
resistant cells than TRAIL-sensitive cells (Griffith et al, 1998).
Downregulation of caspase-8 was also reported in TRAIL-resistant
Ewing’s sarcoma cells (Kontny et al, 2001). Correlation between
PED/PEA-15 protein or erbB-2 receptor and the TRAIL resistance
was reported in glioma and other cell lines (Cuello et al, 2001; Hao
et al, 2001).
To overcome the resistance of tumour cells to TRAIL, enhanced
effects using combinations of anticancer drugs and TRAIL have
been reported (Lacour et al, 2001). Among them, several
anticancer drugs upregulate the expression of TRAIL-R1 or -R2
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sby both p-53-dependent and -independent mechanisms (Sheikh
et al, 1998). However, the effects of each drug and the mechanisms
of individual cases to enhance the expression of TRAIL receptors
are complicated. In a present study, we established a TRAIL-
resistant glioma cell line that completely lacked the expression of
TRAIL receptors but had wild-type p53, and we examined the
mechanisms for sensitisation to TRAIL-induced apoptosis by
genotoxic agents or UV radiation using a TRAIL-receptor-negative
cell line.
MATERIALS AND METHODS
Reagents and antibodies
Soluble human TRAIL (Apo2L) was purchased from BIOMOL
(Plymouth Meeting, PA, USA). Cisplatin was purchased
from Sigma (St. Louis, MO, USA), and doxorubicin and
camptothecin were purchased from TopoGEN (Columbus, OH,
USA). A goat anti-human TRAIL-R2 Ab was purchased from
DAKO (Kyoto, Japan). Normal goat IgG was purchased from
ZYMED (So. San Francisco, CA, USA), and FITC-conjugated
donkey anti-goat IgG Ab was purchased from BETHYL (Mon-
tgomery, TX, USA). z-VAD-FMK was purchased from PEPTIDE
INSTITUTE (Osaka, Japan).
Cell culture
Human osteosarcoma cell lines, HOS, MG63, NY, SaOS, human
glioma cell lines, T98G, A172, KG-1-C and fibrosarcoma HT1080
were maintained in RPMI 1640 medium (GIBCO, Grand Island,
NY, USA) supplemented with 10% heat-inactivated FCS (Egqui-
tech-Bio, Ingram, TX, USA), 2mml -glutamine, 1 10
 5m b-
mercaptoethanol and 0.1mg/ml of kanamycin at 371Ci na
humidified 5% CO2 atmosphere. Human normal osteoblasts were
purchased from Sanko-junyaku (Tokyo, Japan) and maintained
with Osteoblast Growth Medium (Osteoblast Growth Medium
Bullet Kit). Human normal fibroblasts were obtained in our
laboratory from a single donor who underwent an operation for
osteoarthritis. The #63 glioma cell line was also established in our
laboratory from a patient with glioma. Briefly, tumour cells
obtained by operation were cultured in a flask. The #63 cells used
in this study were cultured in vitro repeatedly more than 63 times
generation after generation but were not cloned.
Measurement of cell viability
We measured cell viability using a crystal violet assay. Briefly,
2 10
4cells were cultured in the presence of TRAIL with or
without cisplatin, doxorubicin or camptothecin in a 96-well
microtiter plate. In each assay, z-VAD-FMK or anti-TRAIL-R2
Ab was added 1h before the addition of TRAIL. After removal of
the medium, cells were stained with 50ml crystal violet solution
(0.5%) for 5min. Then cells were rinsed 10 times in tap water and
the plates were dried on paper. After 1h, 100ml of equal volume
mixtures of ethanol and 0.1m sodium phosphate were added and
the absorbance at 570nm was measured using a Titertek Multiscan
Plus microplate reader (Flow Laboratories Inc., McLean, VA,
USA).
DNA fragmentation assay
The #63 cells were incubated with or without 2.5mm of
camptothecin for 24h and further cultured in the presence or
absence of TRAIL for 24h. Then 2 10
6 cells were washed with
phosphate-buffered saline (PBS), lysed in 30mlo f1 0m m Tris-HCl,
100mm EDTA-Na (pH 8.0), containing 0.5% (w/v) sodium-N-
lauryl sulphate (SDS) and 0.5mg/ml RNase A (Sigma, St Louis,
MO, USA), and incubated at 501C for 30min followed by treatment
with 0.5mg/ml of proteinase K (Sigma, St. Louis, MO, USA) at
501C for 30min. Electrophoresis was performed on 2% agarose gel
and DNA was visualised by ethidium bromide staining.
Flow cytometric analysis
The cell surface TRAIL-R2 expression was measured using flow
cytometric analysis. Briefly, a total of 1 10
6 cells were incubated
with or without each agent in a 24-well plate. Then, anti-TRAIL-R2
Ab or normal goat IgG was added and incubated for 1h on ice.
After washing with PBS, cells were incubated with FITC-
conjugated donkey anti-goat IgG Ab. Flow cytometric analyses
were performed using a FACSCalibur flow cytometer (Becton
Dickinson, Mountain View, CA, USA).
RT-PCR
Total RNA was isolated using the guanidium isothiocyanate
method from the tumour tissue or cells cultured with or without
each agent. Total RNA (5mg) was reverse transcribed with MuLV
reverse transcriptase. Reverse transcription was performed using a
thermal programme of 421C for 60min and 901C for 5min. The
PCR reaction was performed using the following primers: TRAIL-
R1, 50-CTG AGC AAC GCA GAC TCG CTG TCC AC-30 and 50-TCC
AAG GAC ACG GCA GAG CCT GTG CCAT-30; TRAIL-R2, 50-GCC
TCA TGG ACA ATG AGA TAA AGG TGG CT-30and 50-CCA AAT
CTC AAA GTA CGC ACA AAC GG-30; TRAIL-R3, 50-GAA GAA
TTT GGT GCC AAT GCC ACT G-30 and 50-CTC TTG GAC TTG
GCT GGG AGA TGT G-30; TRAIL-R4, 50-CTT TTC CGG CGG CGT
TCA TGT CCT TC-30 and 50-GTT TCT TCC AGG CTG CTT CCC
TTT GTA G-30. The thermal programme was one cycle at 941C for
5min, 30 cycles of 941C for 1min, 551C for 1min, 721C for 2min,
and 5min at 721C. PCR-amplified products were resolved and
electrophoresed on 2% agarose gel and visualised with ethidium
bromide.
Transfection of the dominant-negative p53 gene into
#63 cells
The construct of the dominant-negative p53 (DN-p53) gene was
designed as previously described (Curtin et al, 2001) and was
donated by Dr Spinella (Dartmouth Medical School, Hanover,
NH). DN-p53 containing plasmid and control vehicle (pcDNA3.1-
MycHisA, Invitrogen, Cavlsbad, CA, USA) was individually
transfected into #63 cells using Effectene Transfection Regent
(Qiagen, Hilden, Germany). After 24h culture, cells were incubated
with the optimal concentration of G-418 and successful transfec-
tants were cloned after 2 weeks culture.
Western blotting
Proteins (5mg) obtained by SDS lysis were separated on 12.5%
polyacrylamide gel. After transfer to a polyvinylidene difluoride
membrane and incubation overnight at 41C with 5% bovine serum
albumin (BSA) in PBS to block nonspecific immunoglobulins, the
membrane was incubated for 1h at room temperature with anti-
p53 monoclonal Ab (Oncogene, Boston, MA, USA). After washing,
the membrane was incubated with HRP-conjugated secondary Ab
for 1h at room temperature, and specific bands were detected
using ECL, according to the manufacturer’s protocol (Amersham,
Arlington Heights, IL, USA).
Statistics
The statistical significance was analysed using Student’s t-test.
Values are presented means7s.d. Differences were considered to
be significant when Po0.05.
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sRESULTS
TRAIL induces apoptosis of human osteosarcoma,
fibrosarcoma and glioma cells but not normal cells
We first examined the cytotoxic effects of TRAIL against some
tumour cell lines, including the newly established tumour cell lines
in our laboratory and normal cells using crystal violet assay as
described in Materials and Methods. As shown in Figure 1A–C, cell
death was induced by exposure to TRAIL for 48h in all tumour
cells except #63, but not in normal osteoblasts or fibroblasts.
Among them, however, #63 glioma cells were resistant to TRAIL. It
was reported that some tumour cells become resistant to TRAIL-
induced cytotoxicity in various ways. To investigate the mechan-
ism for TRAIL resistance of #63 glioma cells, we first performed
RT-PCR to detect the expression of TRAIL receptors. Either
TRAIL-R1 (DR4) or TRAIL-R2 (DR5), which is necessary to induce
a death signal by TRAIL, was detectable in any cell line except #63
glioma cells (Figure 2). TRAIL-R3 (DcR1) was not detectable in
any cell line and TRAIL-R4 (DcR2) was only detected in
osteosarcoma cell lines, such as HOS, NY, SaOS, and normal
osteoblasts and fibroblasts. The expression level of DcR2 had a
tendency to correlate with the sensitivity of TRAIL-induced cell
death. However, #63 glioma cells did not express TRAIL receptors
at all. To deny the possibility that the lack of TRAIL receptors of
#63 cells occurred in vitro during repeated culture, we examined
the expression of TRAIL receptors of original tumour tissue. As
shown in Figure 2 (lower panel), TRAIL receptors were not
expressed in the original tumour tissue, suggesting an important
mechanism for resistance of tumour cells to TRAIL in vivo. Many
tumour cells have been reported to have mutations in the p53
tumour-suppressive gene and it is frequently one possible
mechanism for progression of tumours. Therefore, we investigated
the sequence of p53 gene of #63 cells and confirmed that they had
wild-type p53 (data not shown). Together, #63 cells are unique
tumour cells that completely lack the expression of TRAIL
receptors and have wild-type p53, suggesting a unique mechanism
for the expansion of tumour cells.
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Figure 1 Sensitivity of osteosarcoma, fibrosarcoma, glioma cell lines,
human normal osteoblasts and fibroblasts to TRAIL. (A) After 48h of
culture with 500ngml
 1 of TRAIL, the cell viability of HOS, MG63, NY,
SaOS and osteoblasts was determined by crystal violet assay as described in
Materials and Methods. The means and standard deviations of three
independent experiments are shown. Statistical significance: *Po0.01
compared with controls. (B) After 48h of culture with 2mgml
 1 of TRAIL,
the cell viability of HT1080 and fibroblasts was determined by crystal violet
assay. The means and s.d.’s of five independent experiments are shown.
Statistical significance: *Po0.01 compared with controls. (C) After 48h of
culture with 2mgml
 1 of TRAIL, the cell viability of T98G, A172, KG-1-C,
and #63 was determined by crystal violet assay. The means and s.d.’s of five
independent experiments are shown. Statistical significance: *Po0.01
compared with controls.
TRAIL-receptors
MR 1 R2 R3 R4
HOS
MG63
NY
SaOS
Osteoblast
HT1080
Fibroblast
T98G
A172
KG-1-C
#63
Original tumor
M: DNA size marker
Figure 2 Expression of TRAIL receptors mRNA. RT-PCR was performed
using specific primers to each TRAIL receptor. Total RNA (5mg)
was reverse transcribed and PCR amplified. Each product was electro-
phoresed on 2% agarose gel and was visualised with ethidium bromide. The
length of each PCR product matched that predicted from the sequence
data.
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synergistic cytotoxicity in #63 glioma cells
Recently, the enhanced cytotoxity of anticancer drugs and
TRAIL was reported in several cancer cells. Therefore, we next
studied whether a combination of TRAIL with genotoxic agents
could induce cytotoxicity in #63 glioma cells, which were resistant
to TRAIL-induced cell death. We measured the viability of #63
glioma cells upon exposure to TRAIL with a wide range of
concentrations of cisplatin, doxorubicin or camptothecin using
crystal violet assay. As shown in Figure 3A, cisplatin itself induced
the growth inhibition of #63 glioma cells at concentrations higher
than 5mgml
 1, and it was significantly enhanced in the presence of
TRAIL. As in the case of cisplatin, doxorubicin, which is a
topoisomerase I inhibitor, or camptothecin, which is a topoisome-
rase II inhibitor, induced growth inhibition of #63 glioma cells at
concentrations higher than 1 or 2.5mm, respectively. Each growth
inhibition was also significantly enhanced in the presence of
TRAIL as shown in Figures 3B and C. In addition, cell death
induced by a combination of camptothecin and TRAIL showed
clear changes in morphology that were typical of apoptotic
cell death including decrease in cell size, condensed nucleus
and formation of apoptotic bodies, as shown in Figure 3D.
Moreover, DNA fragmentation induced by camptothecin in
combination with TRAIL confirmed the apoptotic cell death as
shown in Figure 3E.
Treatment of #63 glioma cells with genotoxic agents
induces the functional expression of TRAIL-R2
To explore the possibility that TRAIL-resistant cells restored the
sensitivity of TRAIL-induced apoptosis, we first studied whether
cisplatin could induce TRAIL receptor in #63 glioma cells that had
not expressed TRAIL receptor at all. RT-PCR showed that the
expression of TRAIL-R2 was specifically induced in #63 cells after
treatment with cisplatin (3mgml
 1) as shown in Figure 4. On the
other hand, TRAIL-R1, -R3 and -R4 were not induced by cisplatin.
Other genotoxic agents, such as doxorubicin or camptothecin, also
induced the expression of TRAIL-R2 similarly to UV radiation, as
shown in Figure 4. We next examined the cell surface TRAIL-R2 on
#63 glioma cells by flow cytometric analysis. Cells were treated
with anti-TRAIL-R2 Ab or isotype-matched control IgG and the
cell surface expression of TRAIL-R2 on #63 cells was compared
before and after treatment with genotoxic agents or UV radiation.
As shown in Figure 5, the cell surface expression of TRAIL-R2 was
not detected on untreated #63 cells (top panel). However, it was
induced by each stimulation, confirming the results obtained by
RT-PCR. Lastly, we confirmed that the functional expression of
TRAIL-R2 was the essential mechanism of sensitization of #63 cells
to TRAIL by genotoxic agents using antagonistic anti-TRAIL-R2
Ab. As shown in Figures 6A–D, cell death induced by cisplatin,
doxorubicin, camptothecin or UV radiation in combination with
TRAIL was effectively inhibited by neutralization of TRAIL-R2. In
addition, cell death induced by combinations of genotoxic agents
and TRAIL was inhibited by pan-caspase inhibitor z-VAD-FMK in
a dose-dependent manner. These findings suggest that the
functional cell surface expression of TRAIL-R2 on #63 glioma
cells by genotoxic agents is the essential mechanism of sensitisa-
tion of #63 cells to TRAIL, and the subsequent death signal
through TRAIL-R2 induces apoptosis of #63 cells via activation of
caspases.
DN-p53 inhibits the enhanced cytotoxity of TRAIL with
genotoxic agents or UV radiation
An assay was developed to assess the importance of wild-type p53
on the induction of cell death of #63 cells. Cells were constitutively
transfected with either a DN-p53 expression plasmid or an
insertless control vector. To confirm the successful transfection
of DN-p53 gene, we first performed Western blotting. As shown in
Figure 7A, DN-p53 was successfully expressed in transfected cells
compared with transfectants of empty vector or the original #63
cells, which expressed wild-type p53. Each transfectant was
cultured with each genotoxic agent or under UV radiation. As
shown in Figures 7B–F, cell death was induced in a number of
genotoxic agent-treated cells. In contrast, the viability was
significantly increased in the DN-p53 transfected cells treated
with genotoxic agents or UV radiation. These findings suggest that
inhibition of the p53 function confers a survival advantage to #63
cells and the expression of TRAIL-R2 after exposure to genotoxic
agents or UV radiation.
DISCUSSION
TRAIL/Apo2L is a member of the TNF family and can induce
apoptosis in many tumour cells but not in normal cells. In fact, the
present findings suggest that TRAIL induced apoptosis in eight of
nine tumour cell lines, but not in normal osteoblasts or fibroblasts.
These results are similar to those reported previously. Hao et al
(2001) showed that glioma cell lines were killed by TRAIL and
normal astrocytes were resistant to TRAIL-induced cell death.
Zhang et al (2000) showed that human normal lung fibroblasts,
melanocytes and umbilical vein endothelial cells were resistant to
TRAIL-induced cell death even though they express cell surface
TRAIL-R1 or -R2). Antitumour activity and safety of injection of
TRAIL were also demonstrated in vivo (Ashkenazi et al, 1999a,b;
Walczak et al, 1999). In contrast to Fas, which causes lethal liver
failure (Tanaka et al, 1997), TRAIL is not toxic to normal cells, and
thus is expected to be used for clinical use in cancer therapy.
Recently, Kelley et al (2001) reported no abnormalities associated
with TRAIL injection in cynomolgus monkeys and chimpanzees
and predicted characterizations of efficacy in vivo, pharmacoki-
netics and the safety of TRAIL in humans. Thus, cancer therapy
using TRAIL is now expected clinically.
However, some tumour cells acquire resistance to TRAIL in
various ways. Apoptosis mediated by TRAIL is regulated by the
expression of two death receptors, TRAIL-R1 and TRAIL-R2, and
two decoy receptors, DcR1 and DcR2, that compete with TRAIL-
induced apoptosis (Degli-Esposti et al, 1997a; Marsters et al, 1997;
Ashkenazi et al, 1999a). In previous studies, the expression of
decoy receptors was not correlated with the sensitivity of TRAIL-
induced apoptosis (Griffith et al, 1998; Hao et al, 2001), suggesting
that the expression level of TRAIL receptors alone is not sufficient
to account for the sensitivity to TRAIL-induced apoptosis. Several
studies have suggested intracellular mechanisms for the TRAIL
resistance of tumour cells. The expression level of FLIP was highest
in the TRAIL-resistant melanoma cells and was low or absent in
the sensitive cells, suggesting a correlation between TRAIL-
induced apoptosis and the expression of FLIP (Griffith et al,
1998). TRAIL-resistant Ewing’s sarcoma was shown to have low
levels of caspase-8 both in mRNA and protein levels (Kontny et al,
2001). It has also been reported that PED/PEA-15 protein inhibits
TRAIL-induced apoptosis of glioma cells (Hao et al, 2001), and cell
lines overexpressing the erbB-2 receptor are resistant to
TRAIL-mediated apoptosis (Cuello et al, 2001). Recently, muta-
tions of TRAIL-R1 and -R2 were reported in breast cancers and
these mutations were found more frequently in the metastatic
tumours, suggesting that mutations in TRAIL-R1 and -R2 are
possible mechanisms to escape TRAIL-induced apoptosis of
tumour cells (Shin et al, 2001). In the present study, we first
established a TRAIL-resistant cell line that completely lacked the
expression of TRAIL receptors, which suggests one important
mechanism for tumour cells to escape from TRAIL-induced
apoptosis.
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Figure 3 Cell viability and apoptotic changes in #63 cells treated with combinations of TRAIL and genotoxic agents. The #63 cells were cultured with
various concentrations of cisplatin (A), doxorubicin (B) and camptothecin (C) for 24h and further cultured with or without TRAIL (2mgml
 1) for 48h. Cell
viability was determined by crystal violet assay. The means and s.d.’s of five independent experiments are shown. Statistical significance: *Po0.01, **Po0.05
compared with controls. The #63 cells were cultured with or without camptothecin (2.5mM) and they were further cultured in the presence or absence of
TRAIL (2mgml
 1). Morphological changes were observed under a phase-contrast microscope ( 100) (D) and DNA fragmentation assay was performed
as described in Materials and Methods (E).
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sSome anticancer agents, in addition to UV radiation, have been
shown to overcome the resistance to TRAIL, resulting in a
synergistic effect with TRAIL. Wu et al (1997) reported that
TRAIL-R2 expression was enhanced after doxorubicin exposure
only when wild-type p53 was present, but not in cells where it was
mutated, degraded or not expressed. Sheikh et al (1998) reported
that ionizing radiation induced TRAIL-R2 in p53 wild-type cells,
whereas methyl methane sulphonate regulated the expression of
TRAIL-R2 in a p53-dependent and -independent manner, suggest-
ing a cell-type-specific, trigger-dependent regulation of TRAIL-R2
expression. In contrast, Bachmann et al (2001) suggested that
TRAIL-R1 was downregulated upon UV exposure. In the present
study, we confirmed the mechanisms of restoring the sensitivity by
genotoxic agents or UV radiation to TRAIL-induced apoptosis,
using transfection of DN-p53 in #63 cells. DN-p53 in #63 cells
significantly inhibited the cytotoxity by TRAIL with genotoxic
agents but not completely, suggesting that TRAIL-R2 expression
by genotoxic agents or UV radiation at least partially depends
on wild-type p53. Recently, p53-dependent upregulation of intra-
cellular molecule Bak as in the case of Bax has been reported
(LeBlanc et al, 2002). We observed the expressions of Bax and Bak
in #63 cells, and it was upregulated by genotoxic agents (data not
shown). Although our results using an antagonistic anti-TRAIL-R2
Ab support a potent mechanism of TRAIL resistance of #63 cells
because of the lack of TRAIL receptors, the possibility that
genotoxic agents may modify the signal transducers downstream
of the receptors has to be elucidated. After all, these results suggest
that combinations of anticancer agents and TRAIL might be the
new strategies to overcome TRAIL resistance of tumour cells.
Recently, an immune response of TRAIL was reported. Type I
IFN and anti-CD3 monoclonal antibody induce TRAIL expression
on both CD4
+ and CD8
+ peripheral blood T cells (Kayagaki et al,
1999). Human CD11c
+ blood dendritic cells express TRAIL after
stimulation with either IFN-g or -a (Fanger et al,1 9 9 9 ) ,a n dI F N - b
TRAIL-receptors
MR 1 R 2 R 3 R 4
N.S
Cisplatin
Doxorubicin
Camptothecin
UV
M:DNA size marker
Figure 4 Specific induction of TRAIL-R2 in #63 cells by genotoxic
agents. RT-PCR was performed using specific primers to each TRAIL
receptor. Total RNA (5mg) was extracted from each cell culture with
cisplatin (3mgml
 1), doxorubicin (2.5mM) or camptothecin (2.5mM) for
24h, or UV radiation (321nm) for 5min and another 3h culture. Then
reverse transcription and PCR amplification were performed. Each product
was electrophoresed on 2% agarose gel and was visualised with ethidium
bromide.
0
40
80
120
160
200
C
o
u
n
t
s
100 101 102 103 104
FL1 - H
N.S.
0
40
80
120
160
200
C
o
u
n
t
s
0
40
80
120
160
200
C
o
u
n
t
s
0
40
80
120
160
200
C
o
u
n
t
s
0
40
80
120
160
200
C
o
u
n
t
s
100 101 102 103 104
FL1 - H
100 101 102 103 104
FL1 - H
100 101 102 103 104
FL1 - H
100 101 102 103 104
FL1 - H
UV radiation
Camptothecin
Doxorubicin
Cisplatin
Figure 5 Cell surface TRAIL-R2 expression on #63 cells after treatment
with genotoxic agents. After preculture with or without cisplatin
(3mgml
 1), doxorubicin (2.5mM) or camptothecin (2.5mM) for 24h, or
UV radiation (321nm) for 5min and another 8h culture, cells were
incubated with 10mgml
 1 of anti-TRAIL-R2 Ab (thick line) or normal goat
IgG (thin line) for 1h. After washing with PBS, cells were incubated with
FITC-conjugated secondary Ab. Then flow cytometric analysis was
performed and fluorescence intensity was shown in a logarithmic scale.
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supregulates TRAIL expression on human dendritic cells (Liu et al,
2001). IFN-g or -a upregulates TRAIL expression on human
monocytes (Griffith et al, 1999), and IL-12, an inducer of IFN-g
production, upregulates TRAIL expression on NK cells in the liver,
spleen and lung (Smyth et al, 2001). In fact, TRAIL-deficient mice
increased susceptibility to tumour initiation and metastasis,
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Figure 6 The effects of anti-TRAIL-R2 Ab or pan-caspase inhibitor on cell death after treatment of genotoxic agents and TRAIL. After preculture with
genotoxic agents for 24h, anti-TRAIL Ab or z-VAD-FMK in various concentrations was added 1h before the addition of TRAIL. Then TRAIL (2mgml
 1) was
added to each culture and cell viability was measured by using crystal violet assay. The means and s.d.’s of five independent experiments are shown. Statistical
significance: *Po0.01 compared with controls.
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ssuggesting that TRAIL has an important role for immune
surveillance by T cells, monocytes, dendric cells and NK cells
(Cretney et al, 2002). In the present study, it is suggested
that genotoxic agents not only directly kill tumour cells, but also
induce apoptosis in tumour cells by utilizing an endogenously
programmed cell-killing mechanism. These findings suggest the
possible immune therapy for cancer using genotoxic agents by
enhancing the susceptibility to TRAIL-bearing cytotoxic T, NK,
NKT, dendritic cells and monocytes as well as administration of
soluble TRAIL.
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